Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation

References

• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–87
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Ratta M, Curti A, Fogli M, et al. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients. Exp Hematol 2000; 28: 931–40
   PubMed Web of Science ®Google Scholar
• Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117: 297–305
   PubMed Web of Science ®Google Scholar
• Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108: 805–16
   PubMed Web of Science ®Google Scholar
• Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999; 107: 648–55
   PubMed Web of Science ®Google Scholar
• Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215–22
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 621–7
   PubMed Web of Science ®Google Scholar
• Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93: 2411–19
   PubMed Web of Science ®Google Scholar
• Motta MR, Castellani S, Rizzi S, et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003; 121: 240–50
   PubMedGoogle Scholar
• Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998; 4: 957–62
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992–8
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230–7
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. TGF-beta: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 244–50
   PubMedGoogle Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–103, [erratum appears in Nat Med 1996;2:1267].
   PubMed Web of Science ®Google Scholar
• Qin Z, Noffz G, Mohaupt M, et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997; 159: 770–6
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772–80
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Y, Freeman ME, et al. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003; 101: 4005–12
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Brown RD, Joshua D, et al. DC in multiple myeloma immunotherapy. Cytotherapy 2004; 6: 128–37
   PubMed Web of Science ®Google Scholar
• Felzmann T, Witt V, Wimmer D, et al. Monocyte enrichment from leukapharesis products for the generation of DC by plastic adherence, or by positive or negative selection. Cytotherapy 2003; 5: 391–8
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109–18
   PubMed Web of Science ®Google Scholar
• Reid CD, Stackpoole A, Meager A, et al. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149: 2681–8
   PubMed Web of Science ®Google Scholar
• Suen Y, Lee SM, Aono F, et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001; 3: 365–75
   PubMed Web of Science ®Google Scholar
• Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Meth 1999; 223: 1–15, [erratum appears in J Immunol Meth 1999;224:211].
   PubMed Web of Science ®Google Scholar
• Lewalle P, Rouas R, Lehmann F, et al. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Meth 2000; 240: 69–78
   PubMed Web of Science ®Google Scholar
• Feuerstein B, Berger TG, Maczek C, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Meth 2000; 245: 15–29
   PubMed Web of Science ®Google Scholar
• Araki H, Katayama N, Mitani H, et al. Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. Br J Haematol 2001; 114: 681–9
   PubMed Web of Science ®Google Scholar
• Morse MA, Zhou LJ, Tedder TF, et al. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy [Comment]. Ann Surg 1997; 226: 6–16
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–8
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–26
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T–T help via APC activation. J Exp Med 1996; 184: 747–52
   PubMed Web of Science ®Google Scholar
• Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–9
   PubMed Web of Science ®Google Scholar
• Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94: 459–73
   PubMed Web of Science ®Google Scholar
• Fairchild PJ, Wraith DC. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC [Comment]. Immunol Today 1996; 17: 80–5
   PubMedGoogle Scholar
• Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995; 154: 5851–61
   PubMed Web of Science ®Google Scholar
• Ridgway D. The first 1000 dendritic cell vaccines [Comment]. Cancer Invest 2003; 21: 873–86
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Lau R, Lee SM, et al. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Meth 2002; 267: 173–83
   PubMed Web of Science ®Google Scholar
• Wong EC, Maher VE, Hines K, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001; 3: 19–29
   PubMed Web of Science ®Google Scholar
• Adamson L, Palmborg A, Svensson A, et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy 2004; 6: 363–71
   PubMed Web of Science ®Google Scholar
• Buchler T, Kovarova L, Musilova R, et al. Generation of dendritic cells using cell culture bags: description of a method and review of literature. Hematology 2004; 9: 199–205
   PubMedGoogle Scholar
• de Vries IJ, Eggert AA, Scharenborg NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002; 25: 429–38
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93: 243–51
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–8
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania S, Bennett G, et al. Induction and expansion of aspergillus specific helper and cytotoxic T lymphocytes for immunotherapy of aspergillosis. Blood 2002; 100: 467a
   PubMed Web of Science ®Google Scholar
• Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Meth 1996; 196: 137–51
   PubMed Web of Science ®Google Scholar
• Brossart P, Grunebach F, Stuhler G, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4238–47
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Jourquin F, Tailleux L, et al. CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells. J Leukoc Biol 2002; 72: 1180–9
   PubMed Web of Science ®Google Scholar
• Bjorck P, Banchereau J, Flores-Romo L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int Immunol 1997; 9: 365–72
   PubMed Web of Science ®Google Scholar
• Hori S, Heike Y, Takei M, et al Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. J Immunother 2004;27:27–35.
   PubMed Web of Science ®Google Scholar
• Dietz A, Padley D, Butler G, et al. Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004; 6: 563–70
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Figdor CG. Current issues in delivering DC for immunotherapy. Cytotherapy 2004; 6: 105–10
   PubMed Web of Science ®Google Scholar
• Tazbirkova A, Okai M, Horley DC, et al. Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived DC for immune therapy. Cytotherapy 2003; 5: 31–9
   PubMed Web of Science ®Google Scholar
• Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol 2004; 125: 24–30
   PubMed Web of Science ®Google Scholar